title: Dextran 70 administration after trauma-hemorrhagic shock does not impair cellular immune functions.
abstract: OBJECTIVE
  Although the effects of the colloid dextran 70 on induction of anaphylactoid reactions or reticuloendothelial phagocytosis have been examined previously, its effects on specific cell-mediated immunity after trauma-hemorrhage shock remain unknown.
  
  
  METHODS
  Nonheparinized C3H/HeN mice underwent a laparotomy, were bled, and then maintained at a blood pressure of 35 mm Hg for 60 minutes. Then they were resuscitated with either 4 x the shed blood volume as lactated Ringer's solution (LRS) or 2 x LRS + 1 x dextran 70. Control mice underwent all operative protocols but were neither hemorrhaged, nor resuscitated. At 2 or 24 hours posthemorrhage, serum, splenocytes (SPL), and peritoneal macrophages (pM phi, splenic Mo (sM phi) were obtained. Bioassays were used to determine interleukin-2 (IL-2), IL-3, IL-6, and SPL proliferation.
  
  
  RESULTS
  Trauma-hemorrhage markedly depressed lymphokine release, splenocyte proliferation, and IL-6 release at 2 hours after the insult. The combination of LRS + dextran did not restore lymphocyte functions, but also did not further suppress them. The release of IL-6 by pM phi and sM phi at 2 and 24 hours after dextran infusion and serum IL-6 remained at the same level as in LRS-treated animals.
  
  
  CONCLUSIONS
  The combination of LRS and colloid dextran 70 does not adversely affect ex vivo cell-mediated immune functions during the first 24 hours after its administration after trauma-hemorrhage. Thus, from the immunological standpoint, dextran is a safe resuscitation adjunct.
authors.affiliation: Department of Surgery, Michigan State University, East Lansing 48824-1315.
authors.forename: J F
authors.initials: JF
authors.lastname: Schmand
authors.forename: A
authors.initials: A
authors.lastname: Ayala
authors.forename: M H
authors.initials: MH
authors.lastname: Morrison
authors.forename: I H
authors.initials: IH
authors.lastname: Chaudry
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D002478:Cells, Cultured; D003911:Dextrans / Q000009:adverse effects* / Q000276:immunology; D005440:Fluid Therapy; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000096:biosynthesis / Q000097:blood; D007377:Interleukin-3 / Q000096:biosynthesis / Q000097:blood; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D010537:Peritoneum / Q000166:cytology; D011897:Random Allocation; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000276:immunology*; D012774:Shock, Traumatic / Q000188:drug therapy / Q000276:immunology*; D013154:Spleen / Q000166:cytology; D006377:T-Lymphocytes, Helper-Inducer / Q000378:metabolism
chemical_list: D003911:Dextrans; D007376:Interleukin-2; D007377:Interleukin-3; D015850:Interleukin-6